Outlook Therapeutics, Inc. OTLK 深 沪
等待开盘 08-14 09:30:00 美东时间
0.8888
-0.211
-19.20%
华盛通- 最 高0.8918
- 今 开0.769
- 成交量 8234.23万股
- 最 低 0.7602
- 昨 收 1.10
- 总市值 1.66亿
- 52周最高 3.39
- 市盈率 静 --
- 换手率 44.03%
- 52周最低 0.1611
- 委 比 -93.20%
- 总股本 1.87亿
- 历史最高 219.20
- 量 比 12.49
- 振 幅 11.96%
- 历史最低 0.1611
- 每 手 1
- 风险率 0.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Outlook Therapeutics Q3 2026 Earnings Preview
Outlook Therapeutics (OTLK) is scheduled to announce Q3 earnings results on Friday, August 14th, before market open. The consensus EPS Estimate is -$0.07 (+84.1% Y/Y) and the consensus Revenue Estimat...
今天 02:43
Outlook Therapeutics slides after pricing $55M securities offering
Outlook Therapeutics (OTLK) shares fell nearly 15% in premarket trading Thursday after the company priced a public offering of 55.6M shares and warrants for gross proceeds of about $55M. The combined ...
08-13 16:17
Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks
The latest update is out from Outlook Therapeutics ( ($OTLK) ). On July 24, 202...
08-13 04:37
Outlook Therapeutics Launches Underwritten Public Offering Of Common Stock And Warrants To Fund LYTENAVA Launch; No Financial Terms Disclosed
Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has commenced an underwritten public offer...
08-13 04:12
美股大行评级 | ITG、Bending Spoons获多家大行首予买入评级；瑞银下调微软目标价从510美元降至480美元
今日重点评级关注：BTIG：上调Outlook Therapeutics"买入"评级，目标价4美元；TD Cowen：维持Nakamoto"买入"评级，目标价从1美元升至17美元
07-28 11:34
Outlook gains approval for ophthalmic bevacizumab for wet AMD
The US FDA has approved Outlook Therapeutics' (OTLK) Lytenava (bevacizumab-vikg) for wet AMD. Lytevana is the first ophthalmic bevacizumab approved for the condition. It is expected to launch by the e...
07-25 03:20
Outlook Therapeutics Says FDA Approves LYTENAVA For Treatment Of Neovascular Age-Related Macular Degeneration, Commonly Known As Wet AMD
Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation Company Launches Commercial Franchise Positioned to Establish a New Standard as...
07-25 02:41
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
Outlook Therapeutics' LYTENAVA, an FDA-approved ophthalmic bevacizumab, becomes the first specifically developed for intravitreal administration to treat wet AMD. The approval marks a significant milestone in retina care, offering a purpose-built formulation with rigorous clinical backing and manufacturing consistency. With anticipated 12 years of market exclusivity under BPCIA, LYTENAVA aims to establish a new standard in the $8.5 billion U.S. r...
07-24 18:40
Why Is Kalaris Therapeutics Stock Gaining Friday?
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) announced expanded data from its Phase 1a single ascending dose trial evaluating TH103 for the treatment of neovascular age-related macular degeneration. Following the announcement, the stock jumped nearly 18%. The clinical-stage biopharmaceutical company sta...
07-18 01:31
Outlook Therapeutics Shareholders Approve Major Capital Changes
The latest update is out from Outlook Therapeutics ( ($OTLK) ). On July 16, 202...
07-17 17:17
